M

Mirum Pharmaceuticals
D

MIRM

52.390
USD
-0.79
(-1.49%)
مغلق
حجم التداول
30,614
الربح لكل سهم
1
العائد الربحي
-
P/E
-25
حجم السوق
2,514,960,051
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARVN
    -0.600
    (-3.27%)
    17.750 USD
    B
    BCYC
    -0.280
    (-2.35%)
    11.660 USD
    B
    BHAT
    -0.003800
    (-6.50%)
    0.054700 USD
    B
    BHVN
    -2.843
    (-7.15%)
    36.897 USD
    C
    CRVS
    -0.22000
    (-4.99%)
    4.19000 USD
    K
    KURA
    0.11500
    (1.41%)
    8.26500 USD
    O
    OPRA
    -0.720
    (-3.54%)
    19.600 USD
    المزيد
الأخبار
المقالات

العنوان: Mirum Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.